- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03833154
Durvalumab vs placebo med stereootaktisk kroppsstrålningsterapi i tidigt skede oopererad icke-småcellig lungcancer (NSCLC)-patienter / Osimertinib efter SBRT hos patienter med tidigt stadium oopererad NSCLC med en EGFR-mutation (PACIFIC-4)
En fas III, randomiserad, placebokontrollerad, dubbelblind, multicenter, internationell studie av Durvalumab med stereootaktisk kroppsstrålningsterapi (SBRT) för behandling av patienter med icke-resekerat stadium I/II, lymfkörtelnegativ icke-småcell Lungcancer (PACIFIC-4/RTOG-3515) Osimertinib efter SBRT, en enarmskohort för patienter med icke-opererad stadium I/II, lymfkörtelnegativ NSCLC som innehåller en sensibiliserande EGFR-mutation
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.
An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Patients with Stage I/II lymph node negative NSCLC and confirmed to meet all eligibility criteria will be randomized 1:1 to receive either Durvalumab + SoC SBRT or placebo + SoC SBRT.
The primary objective of main cohort is to assess the efficacy of Durvalumab with SoC SBRT compared to placebo with SoC SBRT in terms of PFS. Key secondary is to assess the efficacy of Durvalumab with SoC SBRT compared to placebo with SoC SBRT in terms of Overall Survival (OS).
In addition, a study cohort with a sufficient number of patients harboring an EGFR-TKI sensitizing mutation, will receive Osimertinib treatment after completion of SoC SBRT as definitive treatment of Stage I/II lymph node-negative NSCLC. The primary objective of Osimertinib cohort is to assess efficacy of Osimertinib following SoC SBRT in terms of 4-year PFS. Key secondary objectives include safety, OS and efficacy of Osimertininb treatment with SBRT.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Clayton, Australien, 3168
- Research Site
-
-
-
-
-
Aalst, Belgien, 9300
- Research Site
-
Charleroi, Belgien, 6060
- Research Site
-
Edegem, Belgien, 2650
- Research Site
-
Ghent, Belgien, 9000
- Research Site
-
Leuven, Belgien, 3000
- Research Site
-
-
-
-
-
Barretos, Brasilien, 14784-400
- Research Site
-
Porto Alegre, Brasilien, 90110-270
- Research Site
-
Recife, Brasilien, 52010-075
- Research Site
-
Rio de Janeiro, Brasilien, 22271-110
- Research Site
-
São Paulo, Brasilien, 01327-001
- Research Site
-
Volta Redonda, Brasilien, 27258-000
- Research Site
-
-
-
-
-
Bron, Frankrike, 69677
- Research Site
-
Dijon, Frankrike, 21079
- Research Site
-
Lyon, Frankrike, 69317
- Research Site
-
Nantes, Frankrike, 44202
- Research Site
-
Pierre-Bénite, Frankrike, 69310
- Research Site
-
Toulouse, Frankrike, 31000
- Research Site
-
Villejuif, Frankrike, 94805
- Research Site
-
-
-
-
Alabama
-
Tuscaloosa, Alabama, Förenta staterna, 35401
- Research Site
-
-
Arizona
-
Chandler, Arizona, Förenta staterna, 85224
- Research Site
-
Phoenix, Arizona, Förenta staterna, 85004
- Research Site
-
Tucson, Arizona, Förenta staterna, 85719
- Research Site
-
-
California
-
Duarte, California, Förenta staterna, 91010
- Research Site
-
Long Beach, California, Förenta staterna, 90806
- Research Site
-
Los Angeles, California, Förenta staterna, 90095
- Research Site
-
San Diego, California, Förenta staterna, 92123
- Research Site
-
-
Delaware
-
Newark, Delaware, Förenta staterna, 10709
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20010
- Research Site
-
-
Florida
-
Bay Pines, Florida, Förenta staterna, 33744
- Research Site
-
Jacksonville, Florida, Förenta staterna, 32256
- Research Site
-
Miami Beach, Florida, Förenta staterna, 33140
- Research Site
-
Orlando, Florida, Förenta staterna, 32804
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Research Site
-
Atlanta, Georgia, Förenta staterna, 30342
- Research Site
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60612
- Research Site
-
Chicago, Illinois, Förenta staterna, 60637
- Research Site
-
Chicago, Illinois, Förenta staterna, 60611
- Research Site
-
Decatur, Illinois, Förenta staterna, 62526
- Research Site
-
Elmhurst, Illinois, Förenta staterna, 60126
- Research Site
-
Naperville, Illinois, Förenta staterna, 60540
- Research Site
-
-
Indiana
-
Fort Wayne, Indiana, Förenta staterna, 46845
- Research Site
-
-
Iowa
-
Cedar Rapids, Iowa, Förenta staterna, 52403
- Research Site
-
Iowa City, Iowa, Förenta staterna, 52242
- Research Site
-
-
Kentucky
-
Elizabethtown, Kentucky, Förenta staterna, 42701
- Research Site
-
Lexington, Kentucky, Förenta staterna, 40503
- Research Site
-
Louisville, Kentucky, Förenta staterna, 40202
- Research Site
-
-
Louisiana
-
Metairie, Louisiana, Förenta staterna, 70006
- Research Site
-
New Orleans, Louisiana, Förenta staterna, 70121
- Research Site
-
-
Maine
-
South Portland, Maine, Förenta staterna, 04106
- Research Site
-
-
Maryland
-
Annapolis, Maryland, Förenta staterna, 21401
- Research Site
-
Baltimore, Maryland, Förenta staterna, 21201
- Research Site
-
Rosedale, Maryland, Förenta staterna, 21237
- Research Site
-
Silver Spring, Maryland, Förenta staterna, 20910
- Research Site
-
Towson, Maryland, Förenta staterna, 21204
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48197
- Research Site
-
Detroit, Michigan, Förenta staterna, 48201
- Research Site
-
Royal Oak, Michigan, Förenta staterna, 48073
- Research Site
-
-
Minnesota
-
Duluth, Minnesota, Förenta staterna, 55805
- Research Site
-
Rochester, Minnesota, Förenta staterna, 55905
- Research Site
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63110
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68105
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89169
- Research Site
-
-
New Hampshire
-
Lebanon, New Hampshire, Förenta staterna, 03756
- Research Site
-
-
New Jersey
-
Camden, New Jersey, Förenta staterna, 08103
- Research Site
-
Paramus, New Jersey, Förenta staterna, 07652
- Research Site
-
-
New York
-
Albany, New York, Förenta staterna, 12206
- Research Site
-
East Syracuse, New York, Förenta staterna, 13057
- Research Site
-
New Hyde Park, New York, Förenta staterna, 11042
- Research Site
-
New York, New York, Förenta staterna, 10016
- Research Site
-
Rochester, New York, Förenta staterna, 14642
- Research Site
-
Stony Brook, New York, Förenta staterna, 11794
- Research Site
-
Syracuse, New York, Förenta staterna, 13210
- Research Site
-
The Bronx, New York, Förenta staterna, 10461
- Research Site
-
The Bronx, New York, Förenta staterna, 10467
- Research Site
-
-
North Carolina
-
Winston-Salem, North Carolina, Förenta staterna, 27157
- Research Site
-
-
North Dakota
-
Grand Forks, North Dakota, Förenta staterna, 58201
- Research Site
-
-
Ohio
-
Akron, Ohio, Förenta staterna, 44304
- Research Site
-
Blue Ash, Ohio, Förenta staterna, 45242
- Research Site
-
Cincinnati, Ohio, Förenta staterna, 45219
- Research Site
-
Cleveland, Ohio, Förenta staterna, 44106
- Research Site
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97213
- Research Site
-
Portland, Oregon, Förenta staterna, 97210
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19107
- Research Site
-
Pittsburgh, Pennsylvania, Förenta staterna, 15212
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29425
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Förenta staterna, 57105
- Research Site
-
Watertown, South Dakota, Förenta staterna, 57201
- Research Site
-
-
Texas
-
Austin, Texas, Förenta staterna, 78745
- Research Site
-
Dallas, Texas, Förenta staterna, 75235
- Research Site
-
Houston, Texas, Förenta staterna, 77030
- Research Site
-
Sherman, Texas, Förenta staterna, 75090
- Research Site
-
-
Vermont
-
Burlington, Vermont, Förenta staterna, 05401
- Research Site
-
-
Virginia
-
Richmond, Virginia, Förenta staterna, 23249
- Research Site
-
-
Washington
-
Bellingham, Washington, Förenta staterna, 98225
- Research Site
-
Seattle, Washington, Förenta staterna, 98195
- Research Site
-
Spokane Valley, Washington, Förenta staterna, 99216
- Research Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Research Site
-
-
-
-
-
Athens, Grekland, 11527
- Research Site
-
Athens, Grekland, 11526
- Research Site
-
Thessaloniki, Grekland, 55236
- Research Site
-
-
-
-
-
Haifa, Israel, 31096
- Research Site
-
Jerusalem, Israel, 91120
- Research Site
-
Kfar Saba, Israel, 95847
- Research Site
-
Petah Tikva, Israel, 49100
- Research Site
-
Ramat Gan, Israel, 52621
- Research Site
-
Tel Aviv, Israel, 64239
- Research Site
-
-
-
-
-
Florence, Italien, 50134
- Research Site
-
Genova, Italien, 16132
- Research Site
-
Milan, Italien, 20132
- Research Site
-
Orbassano, Italien, 10043
- Research Site
-
Padova, Italien, 35128
- Research Site
-
Pavia, Italien, 27100
- Research Site
-
Roma, Italien, 00128
- Research Site
-
Rozzano, Italien, 20089
- Research Site
-
-
-
-
-
Akashi-shi, Japan, 673-8558
- Research Site
-
Bunkyō City, Japan, 113-8677
- Research Site
-
Chūōku, Japan, 104-0045
- Research Site
-
Fukuoka, Japan, 812-8582
- Research Site
-
Hirosaki-shi, Japan, 036-8563
- Research Site
-
Hiroshima, Japan, 734-8551
- Research Site
-
Kobe, Japan, 650-0047
- Research Site
-
Niigata, Japan, 951-8566
- Research Site
-
Osaka, Japan, 541-8567
- Research Site
-
Sakaishi, Japan, 591-8555
- Research Site
-
Sapporo, Japan, 060-8648
- Research Site
-
Sunto-gun, Japan, 411-8777
- Research Site
-
Toyoake-shi, Japan, 470-1192
- Research Site
-
Yokohama, Japan, 241-8515
- Research Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G 1Z2
- Research Site
-
-
Ontario
-
London, Ontario, Kanada, N6A 5W9
- Research Site
-
Toronto, Ontario, Kanada, M5G 2M9
- Research Site
-
Toronto, Ontario, Kanada, M4N 3M5
- Research Site
-
-
Quebec
-
Montreal, Quebec, Kanada, H2X 3E4
- Research Site
-
-
-
-
-
Beijing, Kina, 100142
- Research Site
-
Beijing, Kina, 100021
- Research Site
-
Changchun, Kina, 130021
- Research Site
-
Changsha, Kina, 410013
- Research Site
-
Chengdu, Kina, 610042
- Research Site
-
Fuzhou, Kina, 350005
- Research Site
-
Hangzhou, Kina, 310022
- Research Site
-
Hangzhou, Kina, 310002
- Research Site
-
Hefei, Kina, 230031
- Research Site
-
Jinan, Kina, 250117
- Research Site
-
Nanjing, Kina, 210009
- Research Site
-
Shanghai, Kina, 200032
- Research Site
-
Shanghai, Kina, 200433
- Research Site
-
Shanghai, Kina, 200030
- Research Site
-
Shanghai, Kina, 200002
- Research Site
-
Shenyang, Kina, 100003
- Research Site
-
Suzhou, Kina, 215006
- Research Site
-
Wenzhou, Kina, 325000
- Research Site
-
Wuhan, Kina, 430022
- Research Site
-
Wuhan, Kina, 430030
- Research Site
-
Zhengzhou, Kina, 450008
- Research Site
-
-
-
-
-
Amsterdam, Nederländerna, 1081 HV
- Research Site
-
Groningen, Nederländerna, 9713 GZ
- Research Site
-
Utrecht, Nederländerna, 3584 CX
- Research Site
-
-
-
-
-
Bydgoszcz, Polen, 85-796
- Research Site
-
Elblag, Polen, 02-300
- Research Site
-
Gdansk, Polen, 80-952
- Research Site
-
Katowice, Polen, 40-514
- Research Site
-
Lodz, Polen, 93-513
- Research Site
-
Warsaw, Polen, 02-781
- Research Site
-
-
-
-
-
Hato Rey, Puerto Rico, 00917
- Research Site
-
-
-
-
-
Kazan, Tatarstan, Ryssland, 420029
- Research Site
-
Moscow, Ryssland, 115478
- Research Site
-
Moscow, Ryssland, 105229
- Research Site
-
Moscow, Ryssland, 119421
- Research Site
-
Saint Petersburg, Ryssland, 197758
- Research Site
-
Ufa, Ryssland, 450054
- Research Site
-
Yekaterinburg, Ryssland, 620905
- Research Site
-
-
-
-
-
Badajoz, Spanien, 6006
- Research Site
-
Barcelona, Spanien, 08041
- Research Site
-
L'Hospitalet de Llobregat, Spanien, 08907
- Research Site
-
Madrid, Spanien, 28034
- Research Site
-
Madrid, Spanien, 28046
- Research Site
-
Madrid, Spanien, 28041
- Research Site
-
Madrid, Spanien, 28040
- Research Site
-
Málaga, Spanien, 29010
- Research Site
-
San Sebastián, Spanien, 20014
- Research Site
-
Santiago de Compostela, Spanien, 15706
- Research Site
-
Seville, Spanien, 41013
- Research Site
-
Valencia, Spanien, 46010
- Research Site
-
Zaragoza, Spanien, 50009
- Research Site
-
-
-
-
-
Birmingham, Storbritannien, B9 5SS
- Research Site
-
Leeds, Storbritannien, LS9 7TF
- Research Site
-
London, Storbritannien, EC1A 7BE
- Research Site
-
Manchester, Storbritannien, M20 4BX
- Research Site
-
-
-
-
-
Cheongju-si, Sydkorea, 28644
- Research Site
-
Goyang-si, Sydkorea, 10408
- Research Site
-
Gyeonggi-do, Sydkorea, 13620
- Research Site
-
Seoul, Sydkorea, 03722
- Research Site
-
Seoul, Sydkorea, 05505
- Research Site
-
Seoul, Sydkorea, 06351
- Research Site
-
-
-
-
-
Ankara, Turkiet (Türkiye), 06520
- Research Site
-
Ankara, Turkiet (Türkiye), 06010
- Research Site
-
Istanbul, Turkiet (Türkiye), 34214
- Research Site
-
Izmir, Turkiet (Türkiye), 35340
- Research Site
-
Kocaeli, Turkiet (Türkiye), 41400
- Research Site
-
-
-
-
-
Dresden, Tyskland, 01307
- Research Site
-
Göttingen, Tyskland, 37075
- Research Site
-
Halle, Tyskland, 06120
- Research Site
-
Hanover, Tyskland, 30459
- Research Site
-
Heidelberg, Tyskland, 69126
- Research Site
-
Homburg, Tyskland, 66424
- Research Site
-
Regensburg, Tyskland, 93053
- Research Site
-
Trier, Tyskland, 54292
- Research Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Main Cohort Key Inclusion Criteria:
- Age ≥18 years
- Planned SoC SBRT as definitive treatment
- World Health Organization (WHO)/ECOG PS of 0, 1 or 2
- Life expectancy of at least 12 weeks
- Body weight >30 kg
- Submission of tumor tissue sample if available
- Adequate organ and marrow function required
- Patients with central or peripheral lesions are eligible
- Staging studies must be done during screening (PET-CT within 10 weeks)
- Patients with a history of metachronous NSCLC and synchronous lesions are eligible with some exceptions
Main Cohort Key Exclusion Criteria:
- Mixed small cell and non-small cell cancer
- History of allogeneic organ transplantation
- History of another primary malignancy with exceptions
- History of active primary immunodeficiency
- Epidermal growth factor receptor local testing is strongly recommended prior to enrollment. Patients with a tumor harboring an EGFRm per local testing will be excluded from the main cohort
- Prior exposure to immune-mediated therapy with exceptions
Osimertinib Cohort Key Inclusion Criteria
- Age ≥18 years
- Planned SoC SBRT as definitive treatment
- WHO/ECOG PS of 0, 1, or 2
- Patients with central or peripheral lesions are eligible
- Patients with a history of metachronous NSCLC and synchronous lesions are eligible with some exceptions
- Staging studies must be done during screening (PET-CT within 10 weeks)
- Submission of tumor tissue sample if available
- Confirmation by local laboratory that the tumor harbors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R)
- Adequate bone marrow reserve or organ function required
- Female patients should be using highly effective contraceptive measures
- Male patients should be asked to use barrier contraceptives (ie, condoms) during sex with all partners during the trial and avoid procreation
Osimertinib Cohort Key Exclusion Criteria
-
Mixed small cell and non-small cell cancer
-
Patients with known or increased risk factor for QTc prolongation
-
Treatment with any of the following:
- Preoperative or adjuvant platinum-based or other chemotherapy for the disease under investigation
- Prior treatment with neoadjuvant or adjuvant EGFR TKI
- Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4
-
Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib
-
Any of the following cardiac criteria
- Mean resting corrected QT interval >470 msec, obtained from 3 ECGs
- Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG.
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained -sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval
- Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: SoC SBRT + Durvalumab Therapy (Main Cohort)
SBRT Durvalumab (PD-L1 monoclonal antibody) 1500 mg every 4 weeks [q4w] intravenously [iv] for up to 26 cycles or until progression or other discontinuation criteria are met. |
Durvalumab 1500 mg every 4 weeks [q4w] intravenously [iv] for up to 26 cycles or until progression or other discontinuation criteria are met.
Andra namn:
|
|
Placebo-jämförare: SoC SBRT + Placebo Therapy (Main Cohort)
SBRT Placebo (matching placebo for infusion) every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met. |
Matching placebo for infusion every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met. |
|
Experimentell: SoC SBRT + Osimertinib Therapy (Osimertinib cohort, single-arm, open-label separate cohort)
SBRT Osimertinib 80mg every day [qd] for oral administration up to 36 months or until progression. Osimertinib treatment should start within 7 to 14 days after completion of SBRT |
Osimertinib 80 mg every day [qd] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1 in subpopulation of patients with Stage I/II NSCLC
Tidsram: from randomization up to 6 years
|
Main Cohort |
from randomization up to 6 years
|
|
4-year Progression-Free Survival (4y-PFS) by ICR according to RECIST 1.1 criteria
Tidsram: from treatment start up to 5 years
|
Osimertinib Cohort |
from treatment start up to 5 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression-Free Survival (PFS) assessed by BICR per RECIST 1.1 in all randomised patients with Stage I/II NSCLC
Tidsram: from randomization up to 6 years
|
Main Cohort |
from randomization up to 6 years
|
|
Overall Survival (OS)
Tidsram: from randomization up to 7 years
|
Main Cohort |
from randomization up to 7 years
|
|
Concentration of durvalumab in serum such as peak concentration and trough
Tidsram: 12 weeks after last dose
|
Main Cohort |
12 weeks after last dose
|
|
Detection of ADA neutralising antibodies titers
Tidsram: up to 6 months after last dose
|
Main Cohort |
up to 6 months after last dose
|
|
Health-related quality of life in patients treated with durvalumab with SoC SBRT compared to placebo with SoC SBRT using the EORTC QLQ-C30
Tidsram: from randomization up to 7 years
|
Main Cohort |
from randomization up to 7 years
|
|
Proportion of patients alive and progression free at 24 months from randomisation (PFS24) assessed by BICR according to RECIST 1.1
Tidsram: at 24 months following randomization
|
Main Cohort |
at 24 months following randomization
|
|
Time to progression (TTP) assessed by BICR according to RECIST 1.1
Tidsram: from randomization up to 6 years
|
Main Cohort |
from randomization up to 6 years
|
|
Time to death or distant metastasis (TTDM) assessed by BICR according to RECIST 1.1
Tidsram: from randomization up to 6 years
|
Main Cohort |
from randomization up to 6 years
|
|
Time from randomisation to second progression (PFS2) as defined by local standard clinical practice
Tidsram: from randomization up to 7 years
|
Main Cohort |
from randomization up to 7 years
|
|
Assessment of AEs by CTCAE v 5.0 as measures of the safety and tolerability of Durvalumab with SoC SBRT compared to placebo with SoC SBRT
Tidsram: up to 3 months after last dose
|
Main Cohort |
up to 3 months after last dose
|
|
Assessment of AEs by CTCAE v 5.0 as measures of the safety, tolerability and compliance of osimertinib with SoC SBRT therapy
Tidsram: Up to 35 days after last dose
|
Osimertinib Cohort |
Up to 35 days after last dose
|
|
WHO performance status
Tidsram: from treatment start up to 5 years
|
Osimertinib Cohort |
from treatment start up to 5 years
|
|
ECG QT interval
Tidsram: Up to 156 weeks of treatment or treatment discontinuation
|
Osimertinib Cohort |
Up to 156 weeks of treatment or treatment discontinuation
|
|
Overall Survival
Tidsram: from treatment start up to 5 years
|
Osimertinib Cohort |
from treatment start up to 5 years
|
|
Time To Progression (TTP)
Tidsram: from treatment start up to 5 years
|
Osimertinib Cohort |
from treatment start up to 5 years
|
|
Time to CNS progression
Tidsram: from treatment start up to 5 years
|
Osimertinib Cohort |
from treatment start up to 5 years
|
|
PFS2
Tidsram: from treatment start up to 5 years
|
Osimertinib Cohort |
from treatment start up to 5 years
|
|
Site(s) of disease progression
Tidsram: from treatment start up to 5 years
|
Osimertinib Cohort |
from treatment start up to 5 years
|
|
PFS by ICR using RECIST 1.1
Tidsram: from treatment start up to 5 years
|
Osimertinib Cohort |
from treatment start up to 5 years
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Lung cancer mortality
Tidsram: from treatment start up to 5 years
|
Osimertinib Cohort |
from treatment start up to 5 years
|
|
Lung Cancer Mortality
Tidsram: from randomization Up to 5 years
|
Main Cohort |
from randomization Up to 5 years
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- D9103C00001
- 2018 (U.S.S. NIH-anslag/kontrakt)
- 2018-002572-41 (EudraCT-nummer)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Tidsram för IPD-delning
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Kriterier för IPD Sharing Access
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .